anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the genetic sequence and synthesis process of bivalent polypeptide vaccine for both type-A and type-O foot-and-mouth diseases.  The synthetic gene sequence is shown in SEQ ID No. 1 or SEQ ID No. 2, and its encoding amino acid sequence is shown in SEQ ID No. 3 or SEQ ID No. 4.  These two gene sequences are connected serially with green fluorescin gene separately to obtain bivalent polypeptide vaccine fusion genes.  These two bivalent polypeptide vaccine fusion genes are constituted prokaryotic expression vectors separately and are expressed as two kinds of bivalent polypeptide vaccine proteins.  The immunogenicity test of these two kinds of protein shows that the synthetic polypeptide vaccine genes have high immunogenic activity.  The vaccine may be injected to livestock to prevent both type-A and type-O foot-and-mouth diseases, and the vaccine genes may be used in preparing the antigen for detecting the foot-and-mouth diseases.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to experimental toxicology and can be used for prevention of toxic effect of cadmium in experimental animals. For this purpose cadmium sulphate solution is introduced to animals subcutaneously in dose 0.1 mg/kg daily. Preliminarily, 30 minutes before cadmium sulphate introduction, daily, one per day via probe into stomach introduced is acizole in dose 30 mg/kg. ^ EFFECT: method ensures efficient reduction and correction of toxic effect of cadmium in case of chronic poisoning with its compounds. ^ 1 ex, 2 tbl, 7 dwg
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in Warnings and Precautions reflect exposure to ZYNYZ 500 mg as an intravenous infusion every 4 weeks as a single agent in 105 patients with MCC enrolled in the POD1UM-201 trial and in 335 patients with other solid tumors. All patients received ZYNYZ until disease progression or unacceptable toxicity; those in the POD1UM-201 trial received ZYNYZ for up to 24 months. The median duration of exposure of the pooled population was 4.6 months (range: 1 day to 27 months).

The safety of ZYNYZ was evaluated in 105 patients enrolled in the POD1UM-201 trial with metastatic or recurrent locally advanced MCC [see Clinical Studies (14)]. Patients received ZYNYZ 500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months. The median duration of exposure was 5.6 months (range: 1 day to 23 months). The median age of patients who received ZYNYZ was 71 years (range: 38-90); 74% ≥ 65 years; 68% male; 79% White, 20% were race unknown or not reported, and 1% were Asian.

Serious adverse reactions occurred in 22% of patients receiving ZYNYZ. The most frequent serious adverse reactions (≥ 2% of patients) were fatigue, arrhythmia, and pneumonitis.

Permanent discontinuation of ZYNYZ due to an adverse reaction occurred in 11% of patients. These included asthenia, atrial fibrillation, concomitant disease progression of chronic lymphocytic leukemia, demyelinating polyneuropathy, eosinophilic fasciitis, increased transaminases, infusion-related reaction, lung disorder, pancreatitis, polyarthritis, and radiculopathy (1 patient each).

Dosage interruptions due to an adverse reaction occurred in 25% of patients who received ZYNYZ. Adverse reactions or laboratory abnormalities that required dosage interruption in ≥ 2% of patients who received ZYNYZ were increased transaminases, increased lipase, increased amylase, pneumonitis, and pyrexia.

The most common (≥ 10%) adverse reactions that occurred in patients receiving ZYNYZ were fatigue, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, and nausea.

Table 2 and Table 3 summarize adverse reactions and laboratory abnormalities, respectively, that occurred in POD1UM-201.
Reducing scar size after severe burn injuries is an important and challenging medical, technological, and social problem. We have developed a battery-powered pulsed electric field (PEF) device and surface needle electrode applicator to deliver PEFs to the healing dorsal burn wound in rats. The pulsed electric field was used to treat residual burn wounds caused by metal contact in rats starting 10 days after the injury for 4 months every 11 or 22 days for 4 months using varying time applied voltages at 250-350 V range, 400 mA current, 40 pulses, 70 μs duration each, delivered at pulse repetition frequency 10 Hz at 5 locations inside the wound. We found 40%-45% reduction in the scar size in comparison with untreated controls in both upper and lower dorsal locations on rats' backs 2 months after the last PEF application. We have not detected significant histopathological differences in the center of the scars besides the thickness of the newly generated epidermis, which was thicker in the PEF-treated group. We showed that minimally invasively applied PEFs through needle electrodes are effective method and device for treating residual burn wounds in the rat model, reducing the size of the resulting scars, without any adverse reaction.
Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood\<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
Obesity is a complex multifactorial disease in which excess body fat triggers negative health effects. Systemically, obesity causes several changes, such as inflammation, oxidative stress, mitochondrial dysfunction and apoptosis; factors linked to the slow and incomplete epithelial regenerative process. Specifically, in the integumentary system, obesity causes an expansion of the skin's surface area and changes in collagen deposition. Molecular underpinnings of why obesity delays wound healing are still poorly understood. In addition to the primary role of dermal adipocytes in lipid storage and heat insulation, they also promote skin immunity, wound healing and hair follicle cycling. As a consequence of the cellular and dysfunctional adaptations of adipocytes, inflammatory immune alterations, alteration in the expression of proteins genes associated with the blood supply, altered collagen formation through fibroblast senescence and excessive degradation of extracellular matrix proteins are metabolic characteristics of the system in obesity that contribute to sustained inflammation and decreased mechanical resistance of the skin.
Women seeking emergency contraception (EC) frequently report multiple recent episodes of unprotected sex. Although high sensitivity urine pregnancy tests effectively rule-out pregnancy resulting from sex that occurred more than 14 days ago, clinicians are frequently concerned that pregnancy may result from unprotected sex that occurred \<14 days prior to IUD placement. Placement of a copper IUD within 5 days of unprotected sex is a highly effective form of EC. Among 52 Chinese women who reported unprotected intercourse 5-7 days prior to copper IUD insertion, no pregnancies occurred. However, the effectiveness of the copper IUD when unprotected sex occurs 7-14 days prior to IUD placement is unknown. Intrauterine pregnancies rarely occur with a copper IUD in place. As some clinicians are concerned about injuring a pregnancy that occurs with an IUD in place, women who have had unprotected sex 7-14 days prior to requesting IUD placement are typically told they must use another, less effective, contraceptive for 2+ weeks and then return to obtain an IUD. To remove this barrier to emergency placement of a copper IUD, we propose to study rates of pregnancy when a copper IUD is placed "any time a urine pregnancy test is negative." We believe that simplifying guidance regarding the recommended timing of copper IUD placement has the potential to significantly increase the number of women offered "same-day" IUD service.
PURPOSE: The aim of this study was to compare the functional outcomes, recurrence rate, range of motion (ROM) and return to sports activities between arthroscopic Bankart repair (ABR) versus arthroscopic Bankart/SLAP repair (ABR/S) in limited contact-athletes with a type V SLAP lesion in the scenario of recurrent anterior shoulder instability (RASI). Our hypothesis was that there is no difference between the two treatments.
METHODS: Two groups of 45 limited-contact athletes with type V SLAP lesion were created. Group 1 underwent an arthroscopic Bankart repair, while group 2 had an arthroscopic Bankart/SLAP repair. The minimum follow-up period was 2 years. The WOSI and ASES scores were used to assess primary functional outcomes. Recurrence rate, ROM and return to sport were also evaluated.
RESULTS: Significant differences were reported in the WOSI and ASES scores pre- and post-operatively in each group. There were no significant differences between the two groups (P = 0.78 and 0.43). We reported 4 recurrences (8.8 %) in group 1 and 5 (11.1 %) in group 2, with no difference between them (P = 0.62). There were no significant differences between the range of motion of each of the groups as well as between them. More than 90% of the athletes in both groups returned to their previous sporting activities.
CONCLUSIONS: Limited-contact athletes with RASI who have a type V SLAP lesion as their primary diagnosis can be treated using either ABR or ABR/S with equal efficacy. Both treatment alternatives preserve athlete's function, stability, ROM and return to sport.
TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
The invention in this application is a decision-support system that utilizes single system design (SSD) and a proprietary algorithm to determine real change is for each individual patient. It pinpoints right medication and dosage for an individual patient, targets standards for functionality, called Activities of Daily Living (ADLs), and Quality of Life Indicators (QoLIs) to maximize personal health and satisfaction. Further, the system has as hallmarks a specific communication system, provision of coordination of services and a continuum of care for seamless delivery of treatment targeted to the needs of an individual patient and his/her care network. It incorporates data collected from genomic testing, patient entry, and automated devices. It is a safety-enhancing, cost-saving, time-saving system that will address placebo effect. It will utilize a variety of technologies to gather data with flexibility for patient needs. It will utilize machine learning for added safety enhancement.
A pre-loaded sterile container in a storage configuration includes a sterile container that defines a recess with a dry powder composition therein. The dry powder composition includes sterile electrolytes and/or dextrose. The pre-loaded container is configured to allow for the introduction of a prescribed amount of sterile water in the recess for agitation with the dry powder composition when needed by a medical patient. After introduction of the sterile water, the pre-loaded container is in a patient dispensing configuration and contains an IV fluid. The dry powder composition in the sterile container results when an IV fluid in the recess of the sterile container undergoes one or more processes such as sterile filtration, spray drying, lyophilization, and/or gamma radiation. The pre-loaded sterile containers are lightweight and have a long shelf-life as compared to containers or bags that simply hold an IV fluid.
The invention provides a pterodonta composition for treating new coronary pneumonia and application thereof. The pathogenesis of the new coronary pneumonia is to infect new coronary viruses, the invention classifies according to the general principle of eight-dimension dialectical treatment of traditional Chinese medicine, uses the No. 1 prescription, the No. 2 prescription and the No. 3 prescription respectively, and performs integrated comprehensive treatment and conditioning with pertinence, so as to achieve the purposes of dispelling cold, dispelling heat, eliminating dampness, eliminating phlegm, expelling toxin and dispelling plague, finally realize the purposes of eliminating pathogenic factors, strengthening body resistance, consolidating constitution, strengthening body resistance, strengthening self-armed, improving self-existing immunity and self-healing capability, and autonomously fighting and killing viruses. The invention is characterized by inheriting the essence of secret recipe for treating the pestilence disease by doctors for thousands of years, having obvious curative effect and opening up a high-speed way for patients with the pestilence disease to recover early. The laggera pterodonta composition for treating the new coronary pneumonia after the epidemic situation and the application thereof can be used for preventing and treating infectious plague and common respiratory diseases for a long time, and play an important role in healthy China.
The purpose of this study is to determine if low energy, non-thermal, 100 ns pulses can ablate BCCs. The investigators consider this a non-significant risk study because our PulseCure system only applies 0.4 watts to the skin compared to the 40 watts applied by the currently used electrosurgical unit to remove skin lesions, the Hyfrecator. Since the PulseCure applies 1/100 of the energy and does not even heat the skin significantly, it represents a non-significant risk to the patient. Our study will provide the first data on the response of BCCs to these 100 ns pulses. The investigators will first treat three BCCs on BCNS patients with different pulse numbers to determine the pulse number needed to ablate. Once the investigators have the optimal pulse number, the investigators will use it to treat 20 normal patients with sporadic BCCs on their trunks. This should provide sufficient data to conclude whether or not nsPEF can ablate BCCs on normal individuals.
Infectious diseases are a significant burden in global healthcare. Pathogens engage with different host defense mechanisms. However, it is currently unknown if there are disease-specific immune signatures and/or if different pathogens elicit common immune-associated molecular entities to common therapeutic interventions. We studied patients enrolled through the Human Immunology Project Consortium (HIPC), which focuses on immune responses to various infections. Blood samples were collected and analyzed from patients during infection and follow-up time points at the convalescent stage. The study included samples from patients with Lyme disease (LD), tuberculosis (TB), malaria (MLA), dengue virus (DENV), and West Nile virus (WNV), as well as kidney transplant patients with cytomegalovirus (CMV) and polyomavirus (BKV) infections. Using an antibody-based assay, we quantified ~ 350 cell surface markers, cytokines, and chemokines involved in inflammation and immunity. Unique protein signatures were identified specific to the acute phase of infection irrespective of the pathogen type, with significant changes during convalescence. In addition, tumor necrosis factor receptor superfamily member 6 (TNR6), C-C Motif Chemokine Receptor 7 (CCR7), and C-C motif chemokine ligand-1 (CCL1) were increased in the acute and convalescent phases across all viral, bacterial, and protozoan compared to blood from healthy donors. Furthermore, despite the differences between pathogens, proteins were enriched in common biological pathways such as cell surface receptor signaling pathway and response to external stimulus. In conclusion, we demonstrated that irrespective of the pathogen type, there are common immunoregulatory and proinflammatory signals.
Cerebral convexity arachnoid cysts (ACs) only represent around 10-14% of the cysts. Symptomatic ACs in the elderly are rare. We present a 66-year-old woman with headache and a focal epileptic seizure. Imaging revealed a left parietal AC. Conservative management chosen but the patient's neurological condition worsened, and an endoscopic fenestration was then performed. Postoperatively, her symptoms completely resolved and MRI image showed significant shrinkage of the AC.
Once a child is diagnosed with non-severe CAP (community-acquired pneumonia) in the ED, specific radiographic findings and point-of-care CRP testing will identify those who require antibiotic treatment immediately. The next day, results of multiplex respiratory pathogen and urine pneumococcal antigen (UAg, optional) testing will be integrated into the care plan, along with additional clinical information about the child gathered remotely, to ensure that only children at appreciable risk for bacterial infection receive antibiotics. Our care pathway uses already-available testing (NPS) in new ways, integrates newer diagnostics (point-of-care CRP, UAg), and includes properly-timed clinical follow up to change how children with non-severe CAP are managed.The research team will follow-up with the participant and caregiver the next day, 2-5 days, 7-21 days and day 30 post-enrolment to ensure clinical stability.
The present invention relates to a foot cream cosmetic composition including purslanes. More specifically, nano-wave water using wave resonance principles is used as a solvent, and a purslane extract is included as an active ingredient. According to the foot cream cosmetic composition of the present invention, nano-wave water using resonance principles is used as a solvent, so a silky using sense and excellent skin absorption affinity are ensured. Also, a moisturizing agent is treated at a high speed and at high pressure during an emulsifying process. Thus, the size of particles is extremely smaller than pre-emulsion and is more uniformly distributed to rapidly smear into skin without stickiness. Rough and cracked foot skin is rapidly alleviated and becomes better, and hardened corneum is flexibly and softly cared. By including the purslane extract, an anti-inflammatory effect and a soothing effect can be ensured.
Objective: To investigate the clinicopathological features of renal leukocyte chemokine type 2 amyloidosis (ALECT2). Methods: The prevalence, clinical characteristics, renal histopathological features, and renal outcome of 15 patients with ALECT2 by kidney biopsy were collected in the Department of Kidney Pathology, Shanxi Medical University Second Hospital, Taiyuan, China from January 1993 to December 2023. Immunohistochemistry and mass spectrometry for amyloid proteins were carried out. Results: Fifteen patients with ALECT2 were included in the study, representing 12.93% (15/116) of the renal biopsy-proven amyloidosis cases. There were 5 males and 10 females. The median age at diagnosis was 61 years. All patients had various degrees of proteinuria; 7 patients had nephrotic syndrome; 3 patients had renal insufficiency; 7 patients had microscopic hematuria. Renal biopsy showed that strongly orangophilic amyloid proteins distributed mainly in the renal cortical interstitium, vascular walls, the glomerular mesangium and/or glomerular basement membrane. Eight cases were diagnosed with ALECT2 alone and 7 cases combined with other renal diseases, including 4 cases with membranous nephropathy, 2 cases with IgA nephropathy, and 1 case with subacute tubular interstitial nephropathy. ALECT2 patients with concurrent renal disease showed a higher proteinuria level than those without (3.48 g/24 h versus 4.58 g/24 h). All patients were corroborated by immunohistochemistry to exhibit the specific location of LECT2 in the amyloid fibrils. Mass spectrometry analysis revealed LECT2 polypeptide in 9 patients. Except two patients with worsening renal function, the others showed stable renal function during the mean follow-up period of 12.5 months. Conclusions: ALECT2 is the second common type of renal amyloidosis in our center. The majority of ALECT2 patients show concurrent renal diseases, with a high rate of membranous nephropathy. Amyloid deposits distribute mainly in the cortical interstitium of the kidney, the glomerular mesangium and vascular walls. Mass spectrometry is the most sensitive and specific method for detecting LECT2 amyloidosis.
FIELD: medicine, pharmacology. SUBSTANCE: invention proposes a new agent showing actoprotective activity - ammonium succinate of the formula C 4 H 4 O 4 (NH 4 ) 2 . The proposed agent shows the enhanced biological activity as compared other known substances and does not exhibit negative effect on organism at doses administrated. An agent enhances working capacity also. EFFECT: enhanced effectiveness of an agent, broadened pattern of agents. 3 ex, 3 tbl
The invention relates to traditional Chinese medicine fritillary powder for treating pertussis. The traditional Chinese medicine fritillary powder is mainly used for solving the problem that the current drugs for treating pertussis are poor in treatment effect and have side effects. The traditional Chinese medicine fritillary powder is prepared through the steps of weighing 10g of Sichuan fritillary bulb, 5g of long-nosed pit viper, 10g of licorice root and 1.5g of lepidium seeds, and co-grinding into fine powder. The usage and dosage are as follows: the powder is orally taken once in the morning, noon and evening of a day by 1-3g every time. The traditional Chinese medicine fritillary powder has the advantages that the total effective rate for pertussis treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine fritillary powder is free from toxic and side effects.
Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
Surgical protheses, particularly dental protheses, are manufactured in the manner usually employed for working up rubber by mixing a solid, preferably comminuted polymerizate with a liquid monomeric or partially polymerized compound to produce a plastic, kneadable mass, filling a mould of the dental flask type therewith and solidifying the mass therein by polymerization of the liquid material.  Suitable polymerizable compounds are vinyl and acryl compounds and styrol.  A mixed polymerizate or mixtures of polymerizates may be employed for the solid material. Polymerization accelerators, e.g. hydrogen peroxide and benzoyl peroxide and regulators, e.g. turpentine oil, may be employed. Additions such as artificial or natural resins, softeners, soluble colours or insoluble pigments, fillers and cellulose derivatives, e.g. cellulose tripropionate or cellulose ethers, may be employed.  Polymerization is effected at temperatures at which bubble formation does not occur.  The mould may be lined with waterglass, gelatine, polyvinyl alcohol &c.  Articles may be repaired in a manner similar to that employed for rubber protheses. In an example, an interpolymer of methacrylic acid methyl ester and acrylic acid butyl ester, in powdered form, is kneaded with a similar monomeric mixture, together with red and white pigments, to form a rubber-like mass which is then packed into a two-part gypsum dental mould, produced in the usual manner. After closing and pressing the mould-parts together, the mould is again opened and further material introduced to ensure complete filling after which the mould is again closed and heated, first to p  60 DEG  C., then to 80 DEG  C., and finally to 100 or 115 DEG  C.  In a further example, the solid and liquid components comprise acrylic acid methyl ester, acrylic acid nitrile, vinyl acetate and methacrylic acid methyl ester.